March 26, 2025 10:10 AM EDT
News Briefing

Hu­ma­cyte to raise $50M; Acrivon to fo­cus on prex­as­ert­ib in en­dome­tri­al can­cer

ENDPOINTS

Plus, news about Tri­bune Ther­a­peu­tics and Leap Ther­a­peu­tics:

Hu­ma­cyte’s $50M of­fer­ing: The North Car­oli­na biotech is sell­ing 25 mil­lion shares at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Fed­er­al judge nix­es FDA's lab-de­vel­oped test rule, says it ex­ceed­ed agen­cy's au­thor­i­ty

What’s next af­ter Marks? At FDA, ques­tions over more top ex­its and fu­ture vi­sion for drug agency

Marks’ ex­it at FDA rat­tles an al­ready tee­ter­ing biotech in­dus­try

Lil­ly's heart dis­ease drug could be dosed as lit­tle as once a year, study shows

Mer­ck’s PAH drug cuts risk of se­ri­ous events by 76% in tri­al stopped for ef­fi­ca­cy

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times